Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study

1. Yu, J.
2. Bai, Y.
3. Cui, Z.
4. Cheng, C.
5. Ladekarl, M.
6. Cheng, K.-C.
7. Chan, K.S.
8. Yarmohammadi, H.
9. Mauriz, J.L.
10. Zhang, Y.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.21037/JGO-24-315 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus